DelMar Pharmaceuticals Inc (NASDAQ:DMPI) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totalling 88,200 shares, a decrease of 53.1% from the August 30th total of 187,900 shares. Currently, 3.7% of the shares of the company are short sold. Based on an average daily volume of 779,500 shares, the short-interest ratio is presently 0.1 days.
A number of research analysts have issued reports on DMPI shares. ValuEngine lowered shares of DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 2nd. Maxim Group started coverage on shares of DelMar Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating on the stock. Dawson James restated a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Thursday, July 11th. Finally, Zacks Investment Research lowered shares of DelMar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday.
Shares of DelMar Pharmaceuticals stock traded down $0.02 on Friday, reaching $0.41. 285,922 shares of the stock were exchanged, compared to its average volume of 212,053. The firm’s 50 day moving average is $0.60 and its 200-day moving average is $1.16. DelMar Pharmaceuticals has a one year low of $0.40 and a one year high of $7.00. The firm has a market cap of $1.18 million, a PE ratio of -0.13 and a beta of 1.25.
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings results on Tuesday, September 10th. The company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.59). As a group, research analysts predict that DelMar Pharmaceuticals will post -1.2 earnings per share for the current fiscal year.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Featured Story: How is the Producer Price Index calculated?
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.